3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

医学 肿瘤科 乳腺癌 内科学 化疗 完全响应 打开标签 癌症 随机对照试验
作者
Jose Manuel Perez‐García,Javier Cortés,Manuel Ruíz‐Borrego,Marco Colleoni,Agostina Stradella,Begoña Bermejo,Florence Dalenc,Santiago Escrivá-de-Romaní,Lourdes Calvo,Nuria Ribelles,Frederik Marmé,Alfonso Cortés,Cinta Albacar,Géraldine Gebhart,Aleix Prat,Khaldoun Kerrou,Peter Schmid,Sofía Braga,Serena Di Cosimo,María Gión
出处
期刊:The Lancet [Elsevier BV]
卷期号:403 (10437): 1649-1659 被引量:34
标识
DOI:10.1016/s0140-6736(24)00054-0
摘要

Summary

Background

PHERGain was designed to assess the feasibility, safety, and efficacy of a chemotherapy-free treatment based on a dual human epidermal growth factor receptor 2 (HER2) blockade with trastuzumab and pertuzumab in patients with HER2-positive early breast cancer (EBC). It used an 18fluorine-fluorodeoxyglucose-PET-based, pathological complete response (pCR)-adapted strategy.

Methods

PHERGain was a randomised, open-label, phase 2 trial that took place in 45 hospitals in seven European countries. It randomly allocated patients in a 1:4 ratio with centrally confirmed, HER2-positive, stage I–IIIA invasive, operable breast cancer with at least one PET-evaluable lesion to either group A, where patients received docetaxel (75 mg/m2, intravenous), carboplatin (area under the curve 6 mg/mL per min, intravenous), trastuzumab (600 mg fixed dose, subcutaneous), and pertuzumab (840 mg loading dose followed by 420 mg maintenance doses, intravenous; TCHP), or group B, where patients received trastuzumab and pertuzumab with or without endocrine therapy, every 3 weeks. Random allocation was stratified by hormone receptor status. Centrally reviewed PET was conducted at baseline and after two treatment cycles. Patients in group B were treated according to on-treatment PET results. Patients in group B who were PET-responders continued with trastuzumab and pertuzumab with or without endocrine therapy for six cycles, while PET-non-responders were switched to receive six cycles of TCHP. After surgery, patients in group B who were PET-responders who did not achieve a pCR received six cycles of TCHP, and all patients completed up to 18 cycles of trastuzumab and pertuzumab. The primary endpoints were pCR in patients who were group B PET-responders after two treatment cycles (the results for which have been reported previously) and 3-year invasive disease-free survival (iDFS) in patients in group B. The study is registered with ClinicalTrials.gov (NCT03161353) and is ongoing.

Findings

Between June 26, 2017, and April 24, 2019, a total of 356 patients were randomly allocated (71 patients in group A and 285 patients in group B), and 63 (89%) and 267 (94%) patients proceeded to surgery in groups A and B, respectively. At this second analysis (data cutoff: Nov 4, 2022), the median duration of follow-up was 43·3 months (range 0·0–63·0). In group B, the 3-year iDFS rate was 94·8% (95% CI 91·4–97·1; p=0·001), meeting the primary endpoint. No new safety signals were identified. Treatment-related adverse events and serious adverse events (SAEs) were numerically higher in patients allocated to group A than to group B (grade ≥3 62% vs 33%; SAEs 28% vs 14%). Group B PET-responders with pCR presented the lowest incidence of treatment-related grade 3 or higher adverse events (1%) without any SAEs.

Interpretation

Among HER2-positive EBC patients, a PET-based, pCR-adapted strategy was associated with an excellent 3-year iDFS. This strategy identified about a third of patients who had HER2-positive EBC who could safely omit chemotherapy.

Funding

F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
善学以致用应助zhaoa采纳,获得10
1秒前
jiling发布了新的文献求助20
1秒前
AAA完成签到,获得积分10
2秒前
逺航关注了科研通微信公众号
2秒前
明理的青寒完成签到 ,获得积分10
2秒前
2秒前
只道寻常完成签到,获得积分10
2秒前
乐乐应助张婷婷采纳,获得10
3秒前
4秒前
4秒前
莫壘壘发布了新的文献求助10
4秒前
5秒前
5秒前
烂漫梦容发布了新的文献求助10
5秒前
如影随形完成签到 ,获得积分10
6秒前
prayer完成签到,获得积分10
6秒前
6秒前
6秒前
能干的向真应助archaea采纳,获得10
7秒前
在水一方应助阿萨德采纳,获得10
7秒前
小牧鱼完成签到,获得积分10
7秒前
情怀应助涵泽采纳,获得10
7秒前
万能图书馆应助wzy采纳,获得20
7秒前
8秒前
gyy完成签到,获得积分10
8秒前
大力尔芙完成签到,获得积分10
8秒前
YU完成签到,获得积分10
8秒前
9秒前
廉洁发布了新的文献求助10
9秒前
9秒前
zzh关闭了zzh文献求助
10秒前
10秒前
小金鱼儿发布了新的文献求助10
10秒前
11秒前
11秒前
qi发布了新的文献求助10
12秒前
12秒前
12秒前
NexusExplorer应助才下眉头采纳,获得10
12秒前
12秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Christian Women in Chinese Society: The Anglican Story 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3961589
求助须知:如何正确求助?哪些是违规求助? 3507917
关于积分的说明 11138698
捐赠科研通 3240341
什么是DOI,文献DOI怎么找? 1790929
邀请新用户注册赠送积分活动 872649
科研通“疑难数据库(出版商)”最低求助积分说明 803306